SCHEMBL4804779

SCHEMBL4804779

COC(=O)c1ccc(OC(=O)C2CCCCC2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 2/20 0.64
POLB P06746 2/20 0.64
KMT2A Q03164 3/20 0.64
SMN1; SMN2 Q16637 2/20 0.64
HTT P42858 1/20 0.64
TDP1 Q9NUW8 1/20 0.64
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
NPC1 O15118 2/20 0.51
CASP3 P42574 1/20 0.51
RAB9A P51151 1/20 0.51
SENP8 Q96LD8 1/20 0.51
SENP7 Q9BQF6 1/20 0.51
SENP6 Q9GZR1 1/20 0.51
MAPT P10636 4/20 0.50
ALDH1A1 P00352 3/20 0.50
MEN1 O00255 2/20 0.50
EPHX2 P34913 1/20 0.50
HPGD P15428 3/20 0.49
ATM Q13315 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29127198 0.95 KMT2A (0.71) ELANEPOLBKMT2ASMN1; SMN2HTT
SCHEMBL4544913 0.92 ELANE (0.61) ELANEPOLBKMT2ASMN1; SMN2HTT
SCHEMBL24157306 0.92 ELANE (0.61) ELANEPOLBKMT2ASMN1; SMN2HTT
SCHEMBL26866501 0.88 ELANE (0.61) ELANEPOLBKMT2ASMN1; SMN2HTT
SCHEMBL15214808 0.88 ELANE (0.51) ELANEPOLBKMT2ASMN1; SMN2HTT
SCHEMBL23511046 0.86 ELANE (0.55) ELANEPOLBKMT2ASMN1; SMN2HTT
SCHEMBL19431509 0.86 ELANE (0.59) ELANEPOLBKMT2ASMN1; SMN2HTT
SCHEMBL10574401 0.85 KMT2A (0.88) ELANEPOLBKMT2ASMN1; SMN2HTT
SCHEMBL3278885 0.84 KMT2A (0.68) ELANEPOLBKMT2ASMN1; SMN2HTT
SCHEMBL19431516 0.84 ELANE (0.56) ELANEPOLBKMT2ASMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7465719-B2 Carbamic acid compounds comprising an ester or ketone linkage as HDAC inhibitors TOPOTARGET UK LIMITED (GB) 2008-12-16 US disclosed
US-20060058282-A1 Carbamic acid compounds comprising an ester or ketone linkage as hdac inhibitors TOPOTARGET UK LIMITED (GB) 2006-03-16 US disclosed
EP-1583736-A1 CARBAMIC ACID COMPOUNDS COMPRISING AN ESTER OR KETONE LINKAGE AS HDAC INHIBITORS TopoTarget UK Limited (GB) 2005-10-12 EP disclosed
WO-2004065354-A1 CARBAMIC ACID COMPOUNDS COMPRISING AN ESTER OR KETONE LINKAGE AS HDAC INHIBITORS TOPOTARGET UK LIMITED (GB) 2004-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060058282-A1 Carbamic acid compounds comprising an ester or ketone linkage as hdac inhibitors HDAC1, HDAC7, HDAC11 ELANE 2697/4885POLB 2726/4885KMT2A 86/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.